Valuation: Indivior PLC

Market Cap 4.85B 4.25B 3.91B 3.63B 6.9B 463B 6.99B 46.86B 18.24B 227B 18.22B 17.82B 788B P/E 2026 *
12.5x
P/E 2027 * 11x
Enterprise Value 4.91B 4.3B 3.96B 3.67B 6.98B 468B 7.07B 47.38B 18.44B 230B 18.43B 18.02B 797B EV / Sales 2026 *
3.9x
EV / Sales 2027 * 3.4x
Free-Float
97.19%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%+4.78% - - 4.85B
-1.14%-2.43%+55.27%+159.07% 1,082B
-1.41%+0.32%+67.02%+60.48% 633B
-2.42%+0.18%+35.78%+85.62% 461B
-2.79%+1.37%+31.00%+23.05% 338B
-2.46%-1.52%+36.42%+32.77% 299B
-2.20%-0.93%+27.50%+40.62% 291B
-1.77%+0.99%-28.85%-41.41% 222B
-2.06%+1.63%+25.09%+64.34% 202B
-1.26%+2.60%+15.95%+70.00% 163B
Average -1.42%+4.45%+29.46%+54.95% 410.27B
Weighted average by Cap. -1.65%+5.43%+40.47%+79.80%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.01B 942M 1.79B 120B 1.81B 12.15B 4.73B 58.9B 4.72B 4.62B 204B 1.31B 1.15B 1.05B 979M 1.86B 125B 1.88B 12.63B 4.91B 61.24B 4.91B 4.8B 212B
Net income 414M 363M 334M 310M 589M 39.54B 597M 4B 1.56B 19.41B 1.56B 1.52B 67.28B 473M 414M 381M 354M 672M 45.11B 681M 4.57B 1.78B 22.14B 1.78B 1.74B 76.76B
Net Debt 54.5M 47.73M 43.96M 40.81M 77.49M 5.2B 78.54M 526M 205M 2.55B 205M 200M 8.85B -403M -353M -325M -302M -574M -38.48B -581M -3.9B -1.52B -18.89B -1.51B -1.48B -65.49B
Logo Indivior PLC
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-